Please provide your email address to receive an email when new articles are posted on . HF with preserved ejection fraction is recognized as a major contributor to CV morbidity and mortality and a ...

"Atrial fibrillation and heart failure are growing epidemics, and both beget each other." ---- Jonathan Hsu, MD, MAS, University of California San Diego “Atrial fibrillation and heart failure are ...

Starting a statin may improve outcomes in patients with heart failure with preserved ejection fraction (HFpEF) who are initially free from atherosclerotic cardiovascular disease (ASCVD), according to ...

Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jennifer E. Ho, MD ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

Subclinical heart failure with preserved ejection fraction (HFpEF) was found in about three out of every four patients undergoing catheter ablation for symptomatic atrial fibrillation (AF) in a single ...

Please provide your email address to receive an email when new articles are posted on . Compared with just a few years ago, medical treatment options for HF with preserved ejection fraction have ...

Secretome Therapeutics is currently preparing an open-label, multiple ascending dose phase 1 study to assess STM-01 in patients with HFpEF. The Food and Drug Administration (FDA) has granted Fast ...

Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed. After 12 weeks of treatment, Kansas City Cardiomyopathy ...

A new study added heart failure with preserved ejection fraction (HFpEF) to the growing list of cardiovascular conditions linked to clonal hematopoiesis of indeterminate potential (CHIP), which ...

Martha Gulati, MD, explains how bias and underrepresentation in research lead to misdiagnosis of HFpEF in women and delays in care. Heart failure, particularly HFpEF, is often underdiagnosed or ...